Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

Table 1

Patients who underwent subsequent therapies after vaccine.

Patient	Adjuvant therapy	DFS (months)	Prior treatment (Prevaccine)	Prevaccine LDH	PostvaccineLDH	Postvaccine treatment	Postvaccine treatment LDH	Best Response	Sites of evaluable metastases
2 P.M.	No	12	BioCT	366	627 §	CT	411	SD	Lung, lymph nodes
4 G.D.	HD-IFN	37	no	332	406	CT	310	PR	Lymph nodes
						HD-IL-2
6 T.A.	No	6	CT and RT+surgery for brain metastases	334	281	BioCT	na	PR	Soft tissue
8 C.P.	No	48	Locoregional CT (arm)	256	245	BioCT	na	PD	Soft tissue
11 M.J.	LD-IFN	108	CT	193	265	Surgery, Gamma Knife (brain)	384	𝐂𝐑+^∗	Lung, kidney, skin, lymph nodes
			Lung surgery, BioCT
15 B.F	No	57	Arm perfusion, BioCT, surgery	603§	686§	Surgery	433	𝐏𝐑+^∗	Lymph nodes, soft tissue
17 B.I	No	9	BioCT	236	234	Surgery	254	𝐏𝐑+^∗	Lung, adrenal gland
18 S.L	HD-INF	36	CT (3 different lines)	374	311	CT, RT (brain), anti-CTLA-4 antibodies	708§	PD	Lymph nodes, soft tissue
22 M.C.	LD-IFN	18	No	591§	988§	Hepatic loco-reg CT, DTIC anti-CTLA4ab	493	PR	Liver, soft tissue
23. R.G	HD-IFN	48	Bone RT	299	313	BioCT,Gamma Knife (brain)	na	CR+	Lung, bone
24. B.R	No	24	CT, LD-IFN	236	234	BioCT	na	PD	Lung, soft tissue, lymph nodes

Adj: adjuvant; T: treatment; V: vaccine; HD-IFN: high-dose interferon; BioCT: biochemotherapy; CT: chemotherapy; RT: radiotherapy; LD: low dose; anti-CTLA4ab, anti-CTLA4 monoclonal antibody; §, elevated; ^∗, responses obtained alternating palliative surgery with vaccine.